Decreased Galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Jiang, Jing ^a   Jin, Mei Shan ^a   Kong, Fei ^a   Cao, Donghui ^a   Ma, Hong Xi ^a   Jia, Zhifang ^a   Wang, Yin Ping ^a   Suo, Jian ^a   Cao, Xueyuan ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ECALECTIN; ONCOPROTEIN; PROTEIN TIM 3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PROTEIN EXPRESSION; STOMACH CANCER; STOMACH MUCOSA; SURVIVAL TIME; TISSUE LEVEL; TISSUE MICROARRAY; TUMOR INVASION;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; GALECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84892411125     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081799     Document Type: Article

References (39)

1. Bray F, Jemal A, Grey N, Ferlay J, Forman D (2012) Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol 13:790-801.
2. Caron M, Bladier D, Joubert R (1990) Soluble galactoside-binding vertebrate lectins: a protein family with common properties. Int J Biochem 22: 1379-1385.
3. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, et al. (1994) Galectins: a family of animal beta-galactoside-binding lectins. Cell 76: 597-598.
4. Liu FT, Rabinovich GA (2005) Galectins as modulators of tumour progression. Nat Rev Cancer 5: 29-41.
5. Baldus SE, Zirbes TK, Weingarten M, Fromm S, Glossmann J, et al. (2000) Increased galectin-3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation. Tumour Biol 21: 258-266.
6. Kim SJ, Choi IJ, Cheong TC, Lee SJ, Lotan R, et al. (2010) Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology 138: 1035-1045 e1031-1032.
7. Wada J, Kanwar YS (1997) Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J Biol Chem 272: 6078-6086.
8. Wiersma VR, de Bruyn M, Helfrich W, Bremer E (2013) Therapeutic potential of Galectin-9 in human disease. Med Res Rev 33 Suppl 1: E102-126.
9. Seki M, Oomizu S, Sakata KM, Sakata A, Arikawa T, et al. (2008) Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol 127: 78-88.
10. Veenstra RG, Taylor PA, Zhou Q, Panoskaltsis-Mortari A, Hirashima M, et al. (2012) Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells. Blood 120: 682-690.
11. Keryer-Bibens C, Pioche-Durieu C, Villemant C, Souquere S, Nishi N, et al. (2006) Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer 6: 283.
12. Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, et al. (2005) Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res 11: 2962-2968.
13. Yamauchi A, Kontani K, Kihara M, Nishi N, Yokomise H, et al. (2006) Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer. Breast J 12: S196-200.
14. Liang M, Ueno M, Oomizu S, Arikawa T, Shinonaga R, et al. (2008) Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma. J Cancer Res Clin Oncol 134: 899-907.
15. Kageshita T, Kashio Y, Yamauchi A, Seki M, Abedin MJ, et al. (2002) Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer 99: 809-816.
16. Kadowaki T, Arikawa T, Shinonaga R, Oomizu S, Inagawa H, et al. (2012) Galectin-9 signaling prolongs survival in murine lung-cancer by inducing macrophages to differentiate into plasmacytoid dendritic cell-like macrophages. Clin Immunol 142: 296-307.
17. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, et al. (2008) Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 205: 2763-2779.
18. Sabatos CA, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A, et al. (2003) Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 4: 1102-1110.
19. Wiener Z, Kohalmi B, Pocza P, Jeager J, Tolgyesi G, et al. (2007) TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Invest Dermatol 127: 906-914.
20. Zhuang X, Zhang X, Xia X, Zhang C, Liang X, et al. (2012) Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol 137: 978-985.
21. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, et al. (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6: 1245-1252.
22. Zhang ZY, Dong JH, Chen YW, Wang XQ, Li CH, et al. (2012) Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma. Asian Pac J Cancer Prev 13: 2503-2509.
23. Nobumoto A, Nagahara K, Oomizu S, Katoh S, Nishi N, et al. (2008) Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology 18: 735-744.
24. Kashio Y, Nakamura K, Abedin MJ, Seki M, Nishi N, et al. (2003) Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol 170: 3631-3636.
25. Wiersma VR, de Bruyn M, van Ginkel RJ, Sigar E, Hirashima M, et al. (2012) The glycan-binding protein galectin-9 has direct apoptotic activity toward melanoma cells. J Invest Dermatol 132: 2302-2305.
26. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, et al. (2002) Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415: 536-541.
27. Yan J, Zhang Y, Zhang JP, Liang J, Li L, et al. (2013) Tim-3 expression defines regulatory T cells in human tumors. PLoS One 8: e58006.
28. Nakayama M, Akiba H, Takeda K, Kojima Y, Hashiguchi M, et al. (2009) Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood 113: 3821-3830.
29. Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, et al. (2007) Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 318: 1141-1143.
30. Cao Y, Zhou X, Huang X, Li Q, Gao L, et al. (2013) Tim-3 expression in cervical cancer promotes tumor metastasis. PLoS One 8: e53834.
31. Zhang Y, Ma CJ, Wang JM, Ji XJ, Wu XY, et al. (2012) Tim-3 regulates proand anti-inflammatory cytokine expression in human CD14 + monocytes. J Leukoc Biol 91: 189-196.
32. Hafler DA, Kuchroo V (2008) TIMs: central regulators of immune responses. J Exp Med 205: 2699-2701.
33. Vaitaitis GM, Wagner DH, Jr. (2012) Galectin-9 controls CD40 signaling through a Tim-3 independent mechanism and redirects the cytokine profile of pathogenic T cells in autoimmunity. PLoS One 7: e38708.
34. (2012) Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 100: 1-441.
35. Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, et al. (2009) Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 113: 1957-1966.
36. Sehrawat S, Suryawanshi A, Hirashima M, Rouse BT (2009) Role of Tim-3/galectin-9 inhibitory interaction in viral-induced immunopathology: shifting the balance toward regulators. J Immunol 182: 3191-3201.
37. Lv K, Zhang Y, Zhang M, Zhong M, Suo Q (2012) Galectin-9 ameliorates Con A-induced hepatitis by inducing CD4 (+)CD25(low/int) effector T-Cell apoptosis and increasing regulatory T cell number. PLoS One 7: e48379.
38. Fujihara S, Mori H, Kobara H, Rafiq K, Niki T, et al. (2013) Galectin-9 in cancer therapy. Recent Pat Endocr Metab Immune Drug Discov 7: 130-137.
39. Ngiow SF, Teng MW, Smyth MJ (2011) Prospects for TIM3-Targeted Antitumor Immunotherapy. Cancer Res 71: 6567-6571.